These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17051503)

  • 1. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
    Allavena C; Flandre P; Pugliese P; Valantin MA; Poizot-Martin I; Cabié A; Melliez H; Cuzin L; Duvivier C; Dellamonica P; Raffi F;
    Scand J Infect Dis; 2012 Jan; 44(1):37-43. PubMed ID: 21851330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell JM; Cahn P; Chaves R
    AIDS; 2008 Nov; 22(17):2313-21. PubMed ID: 18981770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.
    Simpson KN; Roberts G; Hicks CB; Finnern HW
    HIV Clin Trials; 2008; 9(4):225-37. PubMed ID: 18753117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tipranavir: a ritonavir-boosted protease inhibitor.
    Croom KF; Keam SJ
    Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
    Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
    Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
    AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
    Katlama C; Esposito R; Gatell JM; Goffard JC; Grinsztejn B; Pozniak A; Rockstroh J; Stoehr A; Vetter N; Yeni P; Parys W; Vangeneugden T;
    AIDS; 2007 Feb; 21(4):395-402. PubMed ID: 17301557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
    de Requena DG; Bonora S; Calcagno A; D'Avolio A; Siccardi M; Fontana S; Milia MG; Sciandra M; Garazzino S; Di Garbo A; Baietto L; Trentini L; Di Perri G
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1066-71. PubMed ID: 18160524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.
    Antoniou T; Raboud JM; Diong C; Su D; Dewhurst N; Buckley V; Kovacs C; Rachlis A; Brunetta J; Smith G; Gough K; Fletcher D; Loutfy MR
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(6):382-9. PubMed ID: 21138833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
    Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
    Yeni P
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
    Zolopa AR; Berger DS; Lampiris H; Zhong L; Chuck SL; Enejosa JV; Kearney BP; Cheng AK
    J Infect Dis; 2010 Mar; 201(6):814-22. PubMed ID: 20146631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.